Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 188-195, 1 March 2010

A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers☆

  • Andrea H. Weinberger

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry, Yale University School of Medicine, 34 Park Street, SAC, Room S-211, New Haven, CT 06519, USA. Tel.: +1 203 974 7598; fax: +1 203 974 7366.
    • ,
  • Erin L. Reutenauer

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Peter I. Jatlow

      Affiliations

    • Departments of Laboratory Medicine and Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Stephanie S. O’Malley

      Affiliations

    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Marc N. Potenza

      Affiliations

    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Child Study Center, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Tony P. George

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Division of Addiction Psychiatry, Department of Psychiatry, University of Toronto and Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, M5T 1R8 Canada

Received 31 July 2009; received in revised form 16 October 2009; accepted 19 October 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ The Clinicaltrials.gov Registration No. for this trial, “Usefulness of Selegiline as an Aid to Quit Smoking,” is NCT00129311.

PII: S0376-8716(09)00399-8

doi:10.1016/j.drugalcdep.2009.10.009

Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 188-195, 1 March 2010

Article Tools

* Image Usage & Resolution